Savara (NASDAQ:SVRA – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Savara and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Savara | N/A | -84.01% | -63.60% |
| Unicycive Therapeutics | N/A | -144.30% | -87.28% |
Valuation & Earnings
This table compares Savara and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Savara | N/A | N/A | -$118.84 million | ($0.53) | -9.73 |
| Unicycive Therapeutics | $680,000.00 | 312.74 | -$26.56 million | ($2.17) | -3.67 |
Unicycive Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
87.9% of Savara shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Savara and Unicycive Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Savara | 1 | 1 | 6 | 1 | 2.78 |
| Unicycive Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Savara presently has a consensus target price of $9.13, suggesting a potential upside of 77.01%. Unicycive Therapeutics has a consensus target price of $24.75, suggesting a potential upside of 210.73%. Given Unicycive Therapeutics’ higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Savara.
Volatility & Risk
Savara has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Summary
Savara beats Unicycive Therapeutics on 7 of the 13 factors compared between the two stocks.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
